pp-192 Solution for infusion
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Solid tumours — uterine carcinosarcoma/sarcoma; multiple solid tumour types
Clinical stage: Phase 2
Modality: Biological (first-in-class anti-Netrin-1 humanised monoclonal antibody)
Mechanism / Target: Blocks Netrin-1 guidance protein that activates pro-survival signalling in cancer cells (via DCC/UNC5 dependence receptors); releases Netrin-1-driven inhibition of apoptosis in tumour cells and restores anti-tumour immune surveillance
Route / form: IV infusion
Differentiation: First-in-class anti-Netrin-1 mAb; novel pro-apoptotic mechanism targeting a cancer survival signal distinct from VEGF or checkpoint pathways; promising signal in uterine sarcoma/carcinosarcoma — rare cancer with no approved second-line therapy;
Manufacturer #39332
Europe-based clinical-stage biotech developing Rx antibody therapies that target a resistance pathway to improve response to chemotherapy and immunotherapy. Lead program is advancing in clinical trials for solid tumors.
None